FDA Approves New HIV Med

Yesterday the FDA approved the second all-in-one daily combination pill for the treatment of HIV infection. The first such medication, Atripla, has been on the market for several years.

Complera, a complete single-tablet regimen containing Janssen Therapeutics’ Edurant (rilpivirine) and Gilead Sciences’ Viread (tenofovir) and Emtriva (emtricitabine), was approved August 10 by the U.S. Food and Drug Administration (FDA), according to an announcement by Gilead. Complera, the second all-in-one fixed-dose combination tablet for people living with HIV, is approved for those starting antiretroviral (ARV) therapy for the first time.

The new combination pill is not yet available in Europe.